Clinical trials: Musculoskeletal Diseases
Facioscapulohumeral Muscular Dystrophy 1
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
This clinical trial is a study to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments of Losmapimod for patients with Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with an open-label…
- Trial name
- FSHD (NCT04004000)
- Testing
- Losmapimod
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Fulcrum Therapeutics
Plantar Fascitis, Heel Pain
SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization
This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from…
- Conditions
- Plantar Fascitis, Heel Pain, Musculoskeletal Diseases
- Trial name
- SURE-PF (NCT07241884)
- Testing
- Arterial Embolization, Extracorporeal shockwave therapy
- Where
- Uzbekistan
- Volunteers
- 45 people
- Sponsor
- CrannMed
Pain, Osteo Arthritis Knee
Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
This is a phase 2, randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee.
- Conditions
- Pain, Osteo Arthritis Knee, Knee Osteoarthritis, Arthritis
- Trial name
- NCT05618782
- Testing
- LEVI-04
- Where
- 13 sites in Czechia, Denmark and 3 more
- Volunteers
- 518 people
- Sponsor
- Levicept
Polymyositis, Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients…
- Trial name
- PRESIDIO (NCT04033926)
- Testing
- KZR-616
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Kezar Life Sciences, Inc.
Polymyositis, Dermatomyositis
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
This was an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM) who completed the double-blind treatment period of Study KZR-616-003, up to…
- Trial name
- NCT04628936
- Testing
- KZR-616
- Where
- 10 sites in United States, Czechia
- Volunteers
- 18 people
- Sponsor
- Kezar Life Sciences, Inc.
Facioscapulohumeral Muscular Dystrophy (FSHD)
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
This is a study to evaluate the safety and efficacy of losmapimod in treating participants with Facioscapulohumeral Muscular Dystrophy (FSHD).
- Trial name
- NCT05397470
- Testing
- Losmapimod
- Where
- 33 sites in United States, Canada and 7 more
- Volunteers
- 260 people
- Sponsor
- Fulcrum Therapeutics
MuSK Myasthenia Gravis
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction.
- Trial name
- NCT05451212
- Testing
- MuSK-CAART
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cabaletta Bio
Pain, Osteoarthritis, Knee
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain
This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe…
- Trial name
- MARS-17 (NCT05838742)
- Testing
- GSK3858279
- Where
- 93 sites in United States, Argentina and 11 more
- Volunteers
- 314 people
- Sponsor
- GlaxoSmithKline
Achondroplasia
Study of Infigratinib in Children With Achondroplasia
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase…
- Trial name
- NCT04265651
- Testing
- Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 84 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Knee Osteoarthritis
Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
- Trial name
- NCT04636229
- Testing
- Amniotic Suspension Allograft
- Where
- 38 sites in United States
- Volunteers
- 516 people
- Sponsor
- Organogenesis
Fibrodysplasia Ossificans Progressiva
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP).
- Trial name
- ANDECAL (NCT06508021)
- Testing
- Andecaliximab
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Ashibio Inc
Facioscapulohumeral Muscular Dystrophy (FSHD)
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
This study is an open-label extension to evaluate the safety and tolerability of long-term dosing of Losmapimod in patients with FSHD1 who participated in the ReDux4 study.
- Trial name
- NCT04264442
- Testing
- Losmapimod
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 76 people
- Sponsor
- Fulcrum Therapeutics
Orthopedic Disorder
CERAMENT™| Bone Void Filler Device Registry
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use.
- Trial name
- NCT04244942
- Testing
- CERAMENT BVF
- Where
- 13 sites in United States
- Volunteers
- 300 people
- Sponsor
- BONESUPPORT AB
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie
Orthopedic Disorder
Elbow Outcomes Clinical Study (WELBOW)
WELBOW study is an international, ambispective and prospective, single arm, multicenter, observational, non-comparative, Post-Market Clinical Follow-up (PMCF).
- Trial name
- WELBOW (NCT04173377)
- Where
- 7 sites in Belgium, Canada and 2 more
- Volunteers
- 310 people
- Sponsor
- Stryker Trauma and Extremities
Orthopedic Disorder, Arthritis Shoulder
Blueprint® Mixed Reality Pilot Study
A pilot Single-Arm, Multicenter, Prospective, Post-Market 6 months Follow-Up Clinical Investigation to Evaluate the Safety and Effectiveness of the Blueprint Mixed Reality HOLOBLUEPRINT™ (HOLOBLUEPRINT™).
- Conditions
- Orthopedic Disorder, Arthritis Shoulder, Arthritis, Degenerative, Cuff Tear Arthropathy
- Trial name
- BLUEMR (NCT06080412)
- Where
- 4 sites in France
- Volunteers
- 44 people
- Sponsor
- Stryker Trauma and Extremities
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with…
- Trial name
- SELECT - PsA 2 (NCT03104374)
- Testing
- Upadacitinib
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 642 people
- Sponsor
- AbbVie
Postoperative Pain, Total Knee Replacement
Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System
The purpose of this study is to gather information about how knee pain changes when small amounts of electricity are delivered to the nerves in the leg.
- Conditions
- Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
- Trial name
- NCT04341948
- Testing
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- SPR Therapeutics, Inc.
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to…
- Trial name
- SELECT-COMPARE (NCT02629159)
- Testing
- Adalimumab, Upadacitinib
- Where
- 370 sites in United States, Argentina and 42 more
- Volunteers
- 1,629 people
- Sponsor
- AbbVie
Muscle Disorder, Musculoskeletal Diseases
HIFEM for Musculoskeletal System Improvement
The goal of this clinical trial is to investigate the effect of the BTL-899 device on improving the Musculoskeletal System in healthy adult volunteers.
- Trial name
- NCT06677086
- Testing
- Treatment with BTL-899
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.